ZA982093B - Dolastatin-15 derivatives in combination with taxanes. - Google Patents

Dolastatin-15 derivatives in combination with taxanes.

Info

Publication number
ZA982093B
ZA982093B ZA9802093A ZA982093A ZA982093B ZA 982093 B ZA982093 B ZA 982093B ZA 9802093 A ZA9802093 A ZA 9802093A ZA 982093 A ZA982093 A ZA 982093A ZA 982093 B ZA982093 B ZA 982093B
Authority
ZA
South Africa
Prior art keywords
combination
dolastatin
taxanes
derivatives
compounds
Prior art date
Application number
ZA9802093A
Other languages
English (en)
Inventor
Teresa Barlozzari
Andreas Haupt
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of ZA982093B publication Critical patent/ZA982093B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA9802093A 1997-03-13 1998-03-12 Dolastatin-15 derivatives in combination with taxanes. ZA982093B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/819,101 US6103698A (en) 1997-03-13 1997-03-13 Dolastatin-15 derivatives in combination with taxanes

Publications (1)

Publication Number Publication Date
ZA982093B true ZA982093B (en) 1999-09-12

Family

ID=25227196

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9802093A ZA982093B (en) 1997-03-13 1998-03-12 Dolastatin-15 derivatives in combination with taxanes.

Country Status (30)

Country Link
US (2) US6103698A (fr)
EP (1) EP0981358B1 (fr)
JP (1) JP2001514659A (fr)
KR (1) KR100555604B1 (fr)
CN (1) CN1157223C (fr)
AT (1) ATE241376T1 (fr)
AU (1) AU728027B2 (fr)
BG (1) BG64338B1 (fr)
BR (1) BR9808249A (fr)
CA (1) CA2282720C (fr)
CO (1) CO4940498A1 (fr)
CZ (1) CZ293905B6 (fr)
DE (1) DE69815100T2 (fr)
DK (1) DK0981358T3 (fr)
ES (1) ES2200317T3 (fr)
HK (1) HK1026851A1 (fr)
HR (1) HRP980125A2 (fr)
HU (1) HU228860B1 (fr)
ID (1) ID23900A (fr)
IL (2) IL131597A0 (fr)
NO (1) NO323894B1 (fr)
NZ (1) NZ337416A (fr)
PL (1) PL197834B1 (fr)
PT (1) PT981358E (fr)
RU (1) RU2218174C2 (fr)
SK (1) SK285133B6 (fr)
TR (1) TR199902244T2 (fr)
TW (1) TWI277426B (fr)
WO (1) WO1998040092A1 (fr)
ZA (1) ZA982093B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010009901A1 (en) * 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
WO2001024763A2 (fr) 1999-10-01 2001-04-12 Immunogen, Inc. Compositions et methodes de traitement du cancer utilisant des immunoconjugues et des agents chimiotherapeutiques
US20040101511A1 (en) * 2000-11-08 2004-05-27 Young Aiping H Combination preparation of a biological response modifier and an anticancer agent and uses thereof
US20050192443A1 (en) * 2000-11-08 2005-09-01 Lorus Therapeutics Inc. Biological response modifier for the treatment of cancer
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Birドメイン結合化合物
WO2007131366A1 (fr) 2006-05-16 2007-11-22 Aegera Therapeutics Inc. Composés de liaison au domaine iap bir
CN102933231B (zh) 2010-02-10 2015-07-29 伊缪诺金公司 Cd20抗体及其用途
AU2011214057B2 (en) 2010-02-12 2016-11-17 Pharmascience Inc. IAP BIR domain binding compounds
JPWO2021246471A1 (fr) * 2020-06-03 2021-12-09
WO2023033129A1 (fr) 2021-09-03 2023-03-09 東レ株式会社 Composition pharmaceutique pour le traitement et/ou la prévention du cancer

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US5676978A (en) 1989-02-14 1997-10-14 Amira, Inc. Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US5278324A (en) * 1990-08-28 1994-01-11 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
MX9102128A (es) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
KR0185440B1 (ko) 1991-08-09 1999-04-01 야마구찌 다까시 신규의 테트라 펩티트 유도체
US5250683A (en) * 1991-09-23 1993-10-05 Florida State University Certain substituted taxanes and pharmaceutical compositions containing them
US5227400A (en) * 1991-09-23 1993-07-13 Florida State University Furyl and thienyl substituted taxanes and pharmaceutical compositions containing them
US5272171A (en) * 1992-02-13 1993-12-21 Bristol-Myers Squibb Company Phosphonooxy and carbonate derivatives of taxol
FR2688518B1 (fr) * 1992-03-13 1994-05-06 Rhone Poulenc Rorer Sa Procede de preparation de derives du taxane.
US5831002A (en) * 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
US5248796A (en) * 1992-06-18 1993-09-28 Bristol-Myers Squibb Company Taxol derivatives
US5254580A (en) * 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
NZ258882A (en) * 1992-12-16 1997-06-24 Basf Ag Antineoplastic peptides and compositions thereof
US5484612A (en) * 1993-09-22 1996-01-16 The Board Of Trustees Of The Leland Stanford Junior University Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin
CA2129282A1 (fr) 1993-09-29 1995-03-30 George Weber Methode de traitement des maladies neoplasiques a l'aide du taxol et du triazofurin
US5447936A (en) * 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
US5494930A (en) * 1994-06-02 1996-02-27 Shimizu; Yuzuru Caribenolide I
US5525613A (en) * 1994-06-16 1996-06-11 Entropin, Inc. Covalently coupled benzoylecgonine ecgonine and ecgonidine
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5543423A (en) * 1994-11-16 1996-08-06 Vertex Pharmaceuticals, Incorporated Amino acid derivatives with improved multi-drug resistance activity
JPH10510812A (ja) 1994-12-15 1998-10-20 ベーカー ノートン ファーマスーティカルズ、インコーポレーテッド タクサン化合物およびテルルおよび/またはセレン化合物の併用により腫瘍の発育を減少させるための方法および組成物

Also Published As

Publication number Publication date
PL197834B1 (pl) 2008-04-30
CA2282720C (fr) 2009-12-29
CZ321199A3 (cs) 2000-02-16
HUP0001381A2 (hu) 2000-10-28
EP0981358B1 (fr) 2003-05-28
HUP0001381A3 (en) 2001-12-28
CZ293905B6 (cs) 2004-08-18
RU2218174C2 (ru) 2003-12-10
PL335579A1 (en) 2000-05-08
DK0981358T3 (da) 2003-09-22
CA2282720A1 (fr) 1998-09-17
IL131597A0 (en) 2001-01-28
ATE241376T1 (de) 2003-06-15
DE69815100D1 (de) 2003-07-03
IL131597A (en) 2006-06-11
CN1157223C (zh) 2004-07-14
CN1252728A (zh) 2000-05-10
ES2200317T3 (es) 2004-03-01
WO1998040092A1 (fr) 1998-09-17
NZ337416A (en) 2001-05-25
KR20000076211A (ko) 2000-12-26
US6632795B1 (en) 2003-10-14
ID23900A (id) 2000-05-25
JP2001514659A (ja) 2001-09-11
TR199902244T2 (xx) 1999-12-21
CO4940498A1 (es) 2000-07-24
EP0981358A1 (fr) 2000-03-01
DE69815100T2 (de) 2004-02-05
KR100555604B1 (ko) 2006-03-03
SK125199A3 (en) 2000-08-14
HRP980125A2 (en) 1999-02-28
BG64338B1 (bg) 2004-10-29
US6103698A (en) 2000-08-15
AU6694598A (en) 1998-09-29
BG103728A (en) 2000-04-28
PT981358E (pt) 2003-09-30
SK285133B6 (sk) 2006-07-07
AU728027B2 (en) 2001-01-04
TWI277426B (en) 2007-04-01
HU228860B1 (en) 2013-06-28
NO994408L (no) 1999-11-10
NO323894B1 (no) 2007-07-16
NO994408D0 (no) 1999-09-10
HK1026851A1 (en) 2000-12-29
BR9808249A (pt) 2000-05-16

Similar Documents

Publication Publication Date Title
EP1181013A4 (fr) Procede et composition pour le traitement du cancer
RS20080167A (en) Novel improved compositions for cancer therapy
NZ245795A (en) The use of paclitaxel formulations with reduced haematologic toxicity to treat tumours
ZA991885B (en) Novel methods and compositions for delivery of taxanes.
FI935821A0 (fi) Fosfonooximetylestrar av taxanderivat
WO2002058694A3 (fr) Procede de traitement de tumeurs et de cancers hematologiques
AU2412695A (en) Taxane class derivative based pharmaceutical compositions
HK1026851A1 (en) Dolastatin-15 derivatives in combination with taxanes.
IL109613A (en) Inclusion complexes of taxol or taxotere or taxus extract formed with cyclodextrins, their preparation and use
ATE554753T1 (de) 2,2'-dithio-bis(ethansulfonat) für den einsatz zur hemmung paclitaxel-induzierter abnormer thermoesthesia
DE69430797D1 (de) C9 taxanderivate und diese enthaltende pharmazeutische zusammensetzungen
WO2002078690A3 (fr) Agents anti-tumoraux taxoides et compositions pharmaceutiques basees sur ces derniers
ATE393624T1 (de) Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
BR0208221A (pt) Combinação de uma taxano e uma cinase dependente de ciclina
NZ514407A (en) C10 carbamoyloxy substituted taxanes as antitumor agents
EP0793499A4 (fr) Procede et composition permettant de reduire le developpement d'une tumeur par association d'un compose du taxane et d'un compose du tellure et/ou du selenium
SI1287854T1 (sl) Kombinacija DMXAA in paklitaksela ali docetakselaproti raku
HUP0103246A2 (hu) C10 karbonát szubsztituált taxánok
CA2206567A1 (fr) Procede et composition permettant de reduire le developpement d'une tumeur par association d'un compose du taxane et d'un compose du tellure et/ou du selenium
HUP0103247A2 (hu) C7 észter szubsztituált taxánok